Corient Private Wealth LLC Sells 365,861 Shares of Precigen, Inc. $PGEN

Corient Private Wealth LLC decreased its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 45.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 431,710 shares of the biotechnology company’s stock after selling 365,861 shares during the period. Corient Private Wealth LLC’s holdings in Precigen were worth $1,805,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. NBC Securities Inc. bought a new position in shares of Precigen in the 4th quarter worth $38,000. Mason Investment Advisory Services Inc. bought a new stake in Precigen in the fourth quarter valued at about $42,000. Abel Hall LLC bought a new stake in Precigen in the fourth quarter valued at about $44,000. NewEdge Advisors LLC bought a new stake in Precigen in the fourth quarter valued at about $45,000. Finally, Asempa Wealth Advisors acquired a new position in Precigen in the fourth quarter valued at about $48,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PGEN shares. Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citizens Jmp lifted their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Finally, HC Wainwright boosted their price objective on shares of Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Precigen has an average rating of “Hold” and a consensus price target of $12.50.

Insider Activity at Precigen

In related news, insider Donald P. Lehr sold 29,131 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $127,011.16. Following the sale, the insider directly owned 755,461 shares of the company’s stock, valued at approximately $3,293,809.96. The trade was a 3.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Rutul R. Shah sold 42,703 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $186,185.08. Following the completion of the transaction, the chief operating officer directly owned 497,751 shares of the company’s stock, valued at approximately $2,170,194.36. The trade was a 7.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 232,968 shares of company stock worth $1,015,740 over the last three months. 41.40% of the stock is currently owned by insiders.

Precigen Trading Up 1.0%

NASDAQ PGEN opened at $5.92 on Tuesday. Precigen, Inc. has a one year low of $1.39 and a one year high of $6.04. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12. The firm has a market cap of $2.11 billion, a P/E ratio of -5.02 and a beta of 1.06. The stock’s 50-day moving average is $4.37 and its 200-day moving average is $4.20.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Sell-side analysts anticipate that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Precigen Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.